The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples